低强度超声选择性抑制体内胶质瘤细胞
该临床前研究显示，低强度脉冲超声（LIPUS）调至0.3 MHz可抑制小鼠胶质瘤细胞，调至0.7 MHz可抑制人胶质瘤细胞；体外使胶质瘤细胞活力降低超过25%（p < 0.001），正常胶质细胞对照降低不到5%；0.7 MHz LIPUS使皮下异种移植瘤重抑制31.1%（p < 0.05）并诱导凋亡。提示声学驱动选择性抑制肿瘤细胞有望用于无创胶质瘤治疗且对周围健康脑组织损伤小。
要点
- LIPUS频率可调：0.3 MHz抑制小鼠胶质瘤细胞，0.7 MHz抑制人胶质瘤细胞
- 体外胶质瘤细胞活力降低>25%，正常胶质细胞降低<5%
- 0.7 MHz LIPUS使异种移植瘤重抑制31.1%并诱导体内凋亡
核心结论
- LIPUS可通过调整频率选择性抑制小鼠和人胶质瘤细胞，在体外和体内均显示抗肿瘤效果且对正常胶质细胞损伤小。
研究设计与样本
- 临床前研究：体外使用小鼠和人胶质瘤细胞系及正常胶质细胞对照，体内使用人胶质瘤细胞皮下异种移植小鼠模型，评估LIPUS调至0.3 MHz和0.7 MHz的效应。
诊断标准与关键数值
- 体外：LIPUS使小鼠和人胶质瘤细胞活力降低超过25%（p < 0.001），正常胶质细胞对照降低不到5%。
- 体内：0.7 MHz LIPUS使皮下异种移植瘤重抑制31.1%（p < 0.05），并诱导凋亡。
临床应用与阅片要点
- 目前为临床前证据，尚不能用于日常影像阅片或报告；提示LIPUS可能作为无创胶质瘤治疗手段，需进一步临床验证。
局限性
- 研究为临床前体外和皮下异种移植模型，未在原位脑肿瘤模型或人体中验证，向临床转化存在不确定性。
以上解读依据论文摘要（全文未开放获取或许可不允许翻译转载）。
英文原文（摘要）· 点击展开
Cancer remains a leading cause of premature death, in part due to the challenge of selectively targeting cancerous cells while preserving healthy tissues. Conventional cancer therapies often cause collateral damage to healthy cells, failing to achieve selective targeting. Here, we demonstrate that low-intensity pulsed ultrasound (LIPUS) can be modulated to selectively inhibit mouse glioma cells when tuned to 0.3 MHz and inhibit human glioma cells when tuned to 0.7 MHz. Tuned LIPUS reduced viability by over 25% in mouse and human glioma cell lines in vitro (p < 0.001), while by less than 5% for normal glial cell controls. LIPUS tuned to 0.7 MHz inhibited tumor weights with 31.1% (p < 0.05) in a subcutaneous xenograft mouse model using human glioma cells and induced apoptosis in vivo. This demonstration of acoustically-driven, selective inhibition of cancer cells suggests promise for non-invasive glioma treatment while causing minimal damage to surrounding healthy brain tissue.
引用
- Zhang H, Zhu J, Qi B, et al. Selective Inhibition of Glioma Cells In Vivo via Low Intensity Ultrasound. Ultrasound Med Biol. 2026. PMID: 42173729. doi:10.1016/j.ultrasmedbio.2026.03.019
供执业医师工作参考，不替代临床判断；数值与分级以指南原文为准。